Dr Graeme Wald: Ledger

Stories naming Dr Graeme Wald. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Role	Organisation	Sources
Chairman	Prota Therapeutics	OneVentures portfolio

Funding announcement

Prota/MCRI completes enrolment of Phase 2b multicentre clinical trial of probiotic oral immunotherapy for the treatment of peanut allergy (PPOIT-003)

Prota Therapeutics finished enrolling 200 children in its Phase 2b peanut allergy immunotherapy trial, with results expected in early 2020; the MCRI-licensed treatment has been backed by OneVentures since inception.

OneVentures portfolio Wed 23 May 2018 Biomedical Translation Fund Murdoch Children's Research Institute National Health & Medical Research Council OneVentures Prota Therapeutics Royal Children's Hospital University of Melbourne WE Buchan Dr Graeme Wald Professor Mimi Tang Dr Suzanne Lipe

Dr Graeme Wald

Roles

Coverage

Prota/MCRI completes enrolment of Phase 2b multicentre clinical trial of probiotic oral immunotherapy for the treatment of peanut allergy (PPOIT-003)